EPIDYOLEX Trademark

Trademark Overview

On Wednesday, July 18, 2018, a trademark application was filed for EPIDYOLEX with the United States Patent and Trademark Office. The USPTO has given the EPIDYOLEX trademark a serial number of 79240362. The federal status of this trademark filing is REGISTERED as of Tuesday, May 26, 2020. This trademark is owned by GW Research Limited. The EPIDYOLEX trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical and veterinary preparations and substances in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for use in the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; pharmaceutical preparations and substances in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; medicinal infusions in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for use in the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome
epidyolex

General Information

Serial Number79240362
Word MarkEPIDYOLEX
Filing DateWednesday, July 18, 2018
Status700 - REGISTERED
Status DateTuesday, May 26, 2020
Registration Number6060891
Registration DateTuesday, May 26, 2020
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 10, 2020

Trademark Statements

Goods and ServicesPharmaceutical and veterinary preparations and substances in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for use in the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; pharmaceutical preparations and substances in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; medicinal infusions in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for use in the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, September 13, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameJazz Pharmaceuticals Research UK Limited
Party Type31 - New Owner After Registration
Legal Entity Type98 - Unknown
AddressGB
Party NameGW Research Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressCambridge CB249BZ
GB
Party NameGW Research Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressCambridge CB24 9BZ
GB
Party NameGW Research Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressCambridge CB24 9BZ
GB

Trademark Events

Event DateEvent Description
Monday, November 5, 2018ASSIGNED TO EXAMINER
Thursday, September 6, 2018SN ASSIGNED FOR SECT 66A APPL FROM IB
Thursday, September 13, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, September 18, 2018APPLICATION FILING RECEIPT MAILED
Wednesday, November 7, 2018ASSIGNED TO EXAMINER
Monday, June 24, 2019ASSIGNED TO EXAMINER
Wednesday, June 26, 2019NON-FINAL ACTION WRITTEN
Thursday, June 27, 2019NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, July 19, 2019REFUSAL PROCESSED BY MPU
Friday, July 19, 2019NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, August 9, 2019REFUSAL PROCESSED BY IB
Friday, January 17, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, January 17, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, January 17, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, January 31, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 19, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, February 19, 2020NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, February 19, 2020NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Friday, February 28, 2020NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Wednesday, February 12, 2020NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Wednesday, February 12, 2020NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Tuesday, March 10, 2020PUBLISHED FOR OPPOSITION
Tuesday, March 10, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 26, 2020REGISTERED-PRINCIPAL REGISTER
Wednesday, August 26, 2020FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Friday, September 25, 2020FINAL DISPOSITION NOTICE SENT TO IB
Saturday, October 17, 2020FINAL DECISION TRANSACTION PROCESSED BY IB
Wednesday, September 15, 2021TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, March 6, 2020NOTIFICATION PROCESSED BY IB
Friday, September 25, 2020FINAL DISPOSITION PROCESSED
Wednesday, September 15, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, September 15, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Saturday, November 20, 2021NEW REPRESENTATIVE AT IB RECEIVED
Thursday, January 30, 2025CHANGE OF NAME/ADDRESS REC'D FROM IB
Monday, May 26, 2025COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Wednesday, September 15, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, September 15, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

Related Keywords

epidyolex syndrome than percent more cannabis residual treatment gestaut lennox dravet